Pregabalin Market is Expected to Grow by USD 153.03 Million from 2022 to 2026, Driven by the Presence of Large Patient Pool Related to Neuropathic Pain

NEW YORK, October 5, 2022 /PRNewswire/ — The Global Pregabalin Market by Application and Geography – Forecast and Analysis 2022-2026 the size should increase by $153.03 million from 2022 to 2026 at a CAGR of 3.74%. Growing presence of large number of neuropathic pain related patients, increase in geriatric population and increasing applications of pregabalin in various diseases are the major factors propelling the growth of the market. However, growing preference for alternatives and stringent regulatory policies may hamper the market growth. For more information on drivers and challenges Request a sample PDF

Technavio has announced its latest market research report titled Global Pregabalin Market 2022-2026

Key Market Dynamics:

  • Market engine: The presence of a large pool of patients related to neuropathic pain is one of the major drivers for the growth of the pregabalin market. Neuropathic pain is associated with various disorders such as diabetic neuropathy, chemotherapy-induced pain, shingles, and herniated disc. There have been increasing cases of these disorders, especially in the geriatric population. Meanwhile, the growing number of people preferring chemotherapy for cancer treatment is fueling cases of chemotherapy-induced pain. Also, according to the CDC, the incidence of shingles is about four per 1,000 people in the United States each year. Overall, there are approximately one million cases of shingles in the United States each year. Such a scenario will result in increased adoption of pregabalin, which in turn will drive the market growth over the forecast period.

  • Market challenges: The growing preference for alternatives is one of the major factors hampering the growth of the pregabalin market. As current treatments are associated with many unmet needs, end users are looking to switch to alternative therapies. For example, diabetic neuropathic pain can be reduced by supplementing essential acids, alpha-lipoic acid, gamma-linolenic acid, and omega-3 fatty acids. Likewise, acupuncture can be an effective way to manage peripheral neuropathy. Acupuncture uses pressure points throughout the body to realign the body’s energy. Thus, the use of these alternative therapies may hamper the growth prospects during the forecast period.

For information on key drivers, trends and additional challenges available with Technavio. Read our sample report now!

Market segmentation

North America will be the leading region with 36% of the market growth during the forecast period. The United States and Canada are the key countries for the pregabalin market in North America. Rising elderly population coupled with established adoption of LYRICA and Cymbalta in new indications and introduction of new drugs for the treatment of neuropathic pain will facilitate the growth of the pregabalin market in North America over the forecast period.

The Neuropathic pain The application segment will contribute the highest market share growth during the forecast period. Neuropathic pain affects 20-30% of patients with diabetic neuropathy. Thus, the demand for pregabalin is increasing owing to the rising cases of diabetic neuropathy, which is driving the growth of the market. Pregabalin is an alternative treatment for people with neuropathic pain that has not responded to other medications. It effectively reduces the symptoms of many neuropathic pains and is positioned as a first-line therapeutic option with exceptional safety and efficacy. These factors will drive the growth of the segment over the forecast period.

See our sample report for additional information on the contribution of all segments and regional opportunities in the report.

Some companies mentioned with their offers

Related reports:

Pharmaceutical Wholesale and Distribution Market by Drug Types and Geography – Forecast and Analysis 2021-2025

Marine Pharmaceuticals Market by Product and Geography – Forecast and Analysis 2022-2026

Pregabalin Market Scope

Report cover

Details

Page number

120

base year

2021

Forecast period

2022-2026

Growth momentum and CAGR

Accelerate at a CAGR of 3.74%

Market Growth 2022-2026

$153.03 million

Market structure

Fragmented

Annual growth (%)

3.27

Regional analysis

North America, Europe, Asia and Rest of the World (ROW)

Successful market contribution

North America at 36%

Main consumer countries

United States, Canada, Germany, China, Japan and Republic of Korea

Competitive landscape

Leading companies, competitive strategies, scope of consumer engagement

Profiled companies

Biomax Biotechnics Pvt. Ltd., Camber Pharmaceuticals Inc., Cipla Ltd., Dr Kumars Pharmaceuticals, Genesis Biotec Inc., HL Healthcare Pvt. Ltd., Lupine Ltd., Medley Pharmaceuticals Ltd., MK Medicine, MSN Laboratories, Neuracle Lifesciences Pvt. Ltd., Novartis AG, Pfizer Inc., Phoenix Biologicals Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Swastik Life Sciences, Torrent Pharmaceuticals Ltd. and Vibcare Pharma Pvt. ltd.

Market dynamics

Parent market analysis, market growth drivers and barriers, analysis of fast and slow growing segments, impact of COVID-19 and future consumer dynamics, and analysis of market conditions for the forecast period.

Personalization area

If our report does not include the data you are looking for, you can contact our analysts and customize the segments.

Contents:

1. Summary

2 Market landscape

3 Market sizing

4 Five forces analysis

5 Market Segmentation by Application

6 Customer Landscape

7 Geographic landscape

8 drivers, challenges and trends

9 Supplier landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a global leader in technology research and consulting. Their research and analysis focuses on emerging market trends and provides actionable insights to help companies identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialist analysts, Technavio’s reporting library consists of over 17,000 reports and counts, spanning 800 technologies, spanning 50 countries. Their customer base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing customer base relies on Technavio’s comprehensive coverage, in-depth research, and actionable market intelligence to identify opportunities in existing markets and potentials and assess their competitive positions in changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Manager
USA: +1 844 364 1100
UK: +44 203 893 3200
E-mail:[email protected]
Website: www.technavio.com/

Global Pregabalin Market 2022-2026

Global Pregabalin Market 2022-2026

Quote

Quote

Show original content to download multimedia:https://www.prnewswire.com/news-releases/pregabalin-market-to-grow-by-usd-153-03-mn-from-2022-to-2026–driven-by-presence-of-large -group-of-patients-related-to-neuropathic-pain—technavio-301640610.html

SOURCETechnavio

Comments are closed.